<section class="mx-auto flex w-full flex-col justify-between bg-white dark:bg-black-95 pt-0 p-0 mb-8 md:mb-18 print:block" data-test-id="card-container"><div class="flex flex-col flex-wrap print:block"><div class="w-full max-w-full"><div class="kW_p1 s_am s_aG s_a3 s_ak"><div class="kW_Iz s_dU"><a data-test-id="logo" title="Home" class="ak_e2 t_ei t_ez" href="/?source=content_type%3Areact%7Csource%3Asite_navigation"><span class="ak_hM t_ei t_ew"><svg class="ak_gz ak_fP ak_hI"><use xlink:href="#logo"></use></svg></span></a></div><header class="rV_Fv t_ei t_el t_es t_ez"><div class="vy_g t_ei t_el t_es s_dS ct_n1" data-test-id="quick-links"><div class="vy_We t_ei t_ek t_eu t_eC s_ct s_bO"><div class="vy_UN s_aC s_ah s_aW"><div class="yk_iV" data-test-id="themes-list"><ul class="yk_mT t_ei"><li class="yk_mU t_ei t_ek s_dI"><a data-test-id="theme-links-item" class="J_0 t_ej t_ek t_ep J_f9 J_fw aW_jl aW_jA aW_jR N_L" href="/earnings/earnings-call-transcripts?source=content_type%3Areact%7Csection%3Amain_content%7Csection_asset%3Athemes%7Cbutton%3Atranscripts%7Cfirst_level_url%3Aarticle"><span class=""><span class="yk_YG iR_vb">Transcripts</span></span></a></li></ul></div></div></div><div class="vy_Wd t_ei t_ek t_es"></div></div><div class="nf_il t_ei t_es"><h1 class="nf_Y s_dS aW_jt aW_jL aW_jR aW_kE aW_kW aW_k1" data-test-id="post-title">Agios Pharmaceuticals, Inc. (AGIO) CEO Jacqualyn Fouse on Q1 2021 Results - Earnings Call Transcript</h1></div><div class="mb-18 flex justify-between text-medium-2-r md:mb-16 rV_RN t_ei t_ek" data-test-id="post-page-meta"><div><span class="nf_K7 nf_gW r_5" data-test-id="post-date">Apr. 29, 2021 12:26 PM ET</span><span class="nf_gW r_5" data-test-id="post-primary-tickers"><a class="vC_Wk" href="/symbol/AGIO?source=content_type%3Areact%7Csection%3Amain_content%7Csection_asset%3Ameta%7Cfirst_level_url%3Aarticle%7Csymbol%3AAGIO">Agios Pharmaceuticals, Inc. (AGIO)</a></span></div></div></header><div class="tt_N9 t_ei t_el t_es s_dS" data-test-id="author-brief"><div class="tt_ei t_ei"><a class="tt_Lj sm_Lj" href="/author/sa-transcripts?source=content_type%3Areact%7Curl_first_level%3Aarticle%7Csection%3Aauthor_brief%3Asa-transcripts%7Csection_asset%3Aauthor_brief%7Cauthor_icon"><div class="flex shrink-0 items-center justify-center relative w-36 h-36 rounded-full" data-test-id="user-pic-wrapper"><img alt="SA Transcripts profile picture" class="dark:text-black-100 flex w-full items-center justify-center overflow-hidden bg-white-96 text-white-96 dark:bg-black-30 rounded-full h-full" data-test-id="user-pic" height="36" loading="lazy" src="https://static3.seekingalpha.com/images/users_profile/000/101/639/small_pic.png" srcset="https://static3.seekingalpha.com/images/users_profile/000/101/639/big_pic.png 2x, https://static3.seekingalpha.com/images/users_profile/000/101/639/big_pic.png 3x" width="36"></div></a><div class="tt_Oa t_ei t_ep t_ez s_cs"><a class="tt_Lj sm_Lj tt_Ji aW_jn aW_jB aW_jR s_dE sm_Ji" data-test-id="author-name" href="/author/sa-transcripts?source=content_type%3Areact%7Curl_first_level%3Aarticle%7Csection%3Aauthor_brief%3Asa-transcripts%7Csection_asset%3Aauthor_brief%7Cauthor_name">SA Transcripts</a><div class="tt_ri t_ei t_eu"><div class="rF_Ru aW_jl aW_jA aW_jQ tt_N8 r_5 aW_jl aW_jA aW_jQ">141.1K<!-- --> <!-- -->Follower<!-- -->s</div></div></div></div><div class="ll_IU" role="none"><button data-state-text="Following" class="J_0 t_ej t_ek t_ep J_fP J_fz aW_jm aW_jC aW_jR js_FS s_af s_bj s_aG s_a3 pL_F7 t_eE tt_wr s_cf aP_i9" data-test-id="follow-button" type="button"><span class=""><span class="js_FU t_ei t_ep" data-state-placeholder="Following"><span class="js_FV">Follow</span></span></span></button></div></div><div class="wD_XP s_dM"><button class="J_0 t_ej t_ek t_ep J_fP J_fz aW_jm aW_jC aW_jR yx_0 t_ej t_ek" data-test-id="play-button" type="button"><span class=""><svg viewBox="0 0 16 16" xmlns="http://www.w3.org/2000/svg" class="yx_CB" data-test-id="play-button-play-svg"><path d="M0 16V0l16 8-16 8z" fill="currentColor"></path></svg><span class="yx_pl">Play Earnings Call</span></span></button></div><div><div class="paywall-full-content ja_f t_ei" data-test-id="article-content"><div class="ja_mg t_eC"><div class="ja_iS ja_E1" data-test-id="content-container"><p>Agios Pharmaceuticals, Inc. (<span class="ticker-hover-wrapper">NASDAQ:<a href="https://seekingalpha.com/symbol/AGIO?hasComeFromMpArticle=false&amp;source=content_type%253Areact%257Csection%253Amain_content%257Cbutton%253Abody_link" title="Agios Pharmaceuticals, Inc.">AGIO</a></span>) Q1 2021 Results Conference Call April 29, 2021 8:00 AM ET</p> <p><strong>Company Participants</strong></p> <p>Holly Manning - Senior Director of Investor Relations</p> <p>Jacqualyn Fouse - Chief Executive Officer</p> <p>Christopher Bowden - Chief Medical Officer</p> <p>Darrin Miles - Chief Commercial Officer</p> <p>Jonathan Biller - Chief Financial Officer and Head of Legal and Corporate Affairs</p> <p>Bruce Car - Chief Scientific Officer</p> <p><strong>Conference Call Participants</strong></p> <p>Alethia Young - Cantor Fitzgerald &amp; Co</p> <p>Mohit Bansal - Citigroup Inc.</p> <p>Peter Lawson - Barclays Bank PLC</p> <p>Tessa Romero - JPMorgan Chase &amp; Co</p> <p>Mark Breidenbach - Oppenheimer &amp; Co. Inc.</p> <p>Kelsey Goodwin - Guggenheim Securities, LLC</p> <p><strong>Operator</strong></p> <p>Good morning, and welcome to Agios' First Quarter 2021 Conference Call. At this time all participants are in a listen-only mode. There will be a question-and-answer session at the end. Please be advised that this call is being recorded at Agios' request.</p> <p>I would now like to turn the call over to Holly Manning, Senior Director of Investor Relations.</p> <p><strong>Holly Manning</strong></p> <p>Thank you, operator. Good morning, everyone, and welcome to Agios' First Quarter 2021 Conference Call. You can access slides for today's call by going to the Investors section of our website, agios.com.</p> <p>With me on the call today with prepared remarks are Dr. Jackie Fouse, our Chief Executive Officer; Dr. Chris Bowden, our Chief Medical Officer; Daren Miles, our Chief Commercial Officer; and Jonathan Biller, our Chief Financial Officer and Head of Legal and Corporate Affairs. Dr. Bruce Carr, our Chief Scientific Officer, will join for Q&amp;A.</p> <p class="iS_EF">Before we get started, I would like to remind everyone that some of the statements we make on this call will include Forward-Looking Statements. Actual events and results could differ materially from those expressed or implied by any forward-looking statements as a result of various risks, uncertainties and other factors, including those<span class="paywall-full-content invisible"> set forth in our most recent filings with the SEC and any other future filings that we may make with the SEC.</span></p> <p class="paywall-full-content invisible">With that, I will turn the call over to Jackie.</p> <p class="paywall-full-content invisible"><strong>Jacqualyn Fouse</strong></p> <p class="paywall-full-content invisible">Thank you, Holly. Good morning, everyone, and thanks for joining our first quarter 2021 results call. The<span class="paywall-full-content no-summary-bullets invisible"> first three months of this year were extremely productive. We closed the sale of our Oncology business, accelerated our late-stage clinical programs for mitapivat and prepared for our first regulatory filings and subsequent commercial launch in pyruvate kinase deficiency.</span></p> <p class="paywall-full-content invisible no-summary-bullets">Back in December, we announced our strategy to focus on genetically defined diseases, including accelerating and unlocking the full potential of mitapivat across its three initial indications in hemolytic anemias as well as leveraging our overall expertise in PK activation and our other research programs.</p> <p class="paywall-full-content invisible no-summary-bullets">To enable this focus, we also announced the decision to sell our oncology programs to Servier to facilitate and fund this strategy. Since that time, nearly a third of our organization has been actively involved in the important and complex process of ensuring a smooth transition of our assets and people to Servier. The transaction was approved by Agios shareholders on March 25, and on April 1<sup>st</sup>, we announced the closing of the sale.</p> <p class="paywall-full-content invisible no-summary-bullets">To each and every oncology employee who helped create truly meaningful differentiated therapies for patients over the past decade, we are grateful for your impassioned work at Agios, and we look forward to watching these programs is with Servier.</p> <p class="paywall-full-content invisible no-summary-bullets">As we look ahead, Agios is poised for a bright and focused future that will build on the important progress we are making now in Q2. This includes finalizing our global regulatory filings for mitapivat and pyruvate kinase deficiency; preparing to initiate two Phase III trials of mitapivat in thalassemia and a Phase II/III trial of mitapivat in sickle cell disease.</p> <p class="paywall-full-content invisible no-summary-bullets">Advancing our patient identification efforts and launch preparations ahead of the potential approval of mitapivat in PK deficiency next year; and finally, initiate the thoughtful execution of up to $1.2 billion in share repurchases that Jonathan will describe in more detail.</p> <p class="paywall-full-content invisible no-summary-bullets">At the heart of this work is our continued commitment to making a significant difference in the lives of the patients we serve. And I would like to take a moment to recognize some of the important efforts we have been pursuing on behalf of patients over recent months.</p> <p class="paywall-full-content invisible no-summary-bullets">First, we are excited to announce a collaboration with 23 &amp; Me that led to the launch of its very first PK deficiency carrier status report, which is a significant step forward in educating the broader population about PK deficiency.</p> <p class="paywall-full-content invisible no-summary-bullets">Second, we announced our sponsorship of Citizen Scientists' Unpacking the Science of Sickle Cell Disease, an initiative developed by the Sickle Cell Community Consortium to promote health literacy for sickle cell patients. Within the Citizen Scientists' initiative, we were also the founding sponsor of a new series of episodes on Cheap Codes, a sickle cell podcast.</p> <p class="paywall-full-content invisible no-summary-bullets">The podcast series brings world-renowned physicians together with patients and caregivers to have real conversations about new sickle cell research emerging from major medical and scientific congresses.</p> <p class="paywall-full-content invisible no-summary-bullets">The goal is to provide the sickle cell community with access to critical information about better ways to manage their health and innovative new treatments in development. The inaugural episodes focused on the presentations from the 2020 ASH Annual Meeting and can be accessed by searching for Sheet Codes wherever you stream your podcast.</p> <p class="paywall-full-content invisible no-summary-bullets">And third, in honor of Rare Disease Day, we hosted a discussion about thalassemia with [Dr. Suzie Chet] (Ph), who runs the New York Comprehensive Thalassemia Center, and his patient, Sam, who has been treated for thalassemia for over 20-years and has a unique perspective on living with the disease. These educational and patient-focused efforts underscore our commitment to making a positive difference in the lives of the people we serve.</p> <p class="paywall-full-content invisible no-summary-bullets">With that, I will now turn the call over to Chris.</p> <p class="paywall-full-content invisible no-summary-bullets"><strong>Christopher Bowden</strong></p> <p class="paywall-full-content invisible no-summary-bullets">Thanks, Jackie. I will start with our most advanced genetically defined disease program, mitapivat, our first-in-class PKR activator currently being evaluated across three distinct chronic hemolytic anemias: hydrovane kinase deficiency, thalassemia and sickle cell disease.</p> <p class="paywall-full-content invisible no-summary-bullets">In pyruvate kinase deficiency, we reported top line data from the ACTIVATE and ACTIVATE-T Phase III studies, evaluating mitapivat in adults with pyruvate kinase deficiency who are not regularly transfused and those who were regularly transfused, respectively.</p> <p class="paywall-full-content invisible no-summary-bullets">We look forward to sharing data from both studies, including patient-reported outcomes data at the European Hematology Association Virtual Congress, which is being held June 9<sup>th</sup> through 17. These data support the potential for mitapivat to be the first disease-modifying therapy for PK deficiency and will be the basis for our global regulatory filing that is currently in process.</p> <p class="paywall-full-content invisible no-summary-bullets">We are on-track to file for regulatory approval in the U.S. this quarter, and in the EU, midyear, with potential 2022 regulatory approvals in both geographies. Darren will speak to our commercial launch preparations in his comments.</p> <p class="paywall-full-content invisible no-summary-bullets">Moving to the Phase II study of mitapivat in thalassemia, we completed enrollment last year with 20 patients, and in June, we will present data on all patients from the core period of this study at EHA. Based on the robust proof-of-concept data from this trial, we designed two global placebo-controlled pivotal trials of mitapivat in thalassemia, ENERGIZE and ENERGIZE-T, which we unveiled in December. ENERGIZE will evaluate 171 patients randomized 2:1 to 100 milligrams of mitapivat VID or placebo in both beta and alpha thalassemia patients who are not regularly transfused.</p> <p class="paywall-full-content invisible no-summary-bullets">The primary endpoint is the percent of patients with a mean hemoglobin increase of greater than or equal to one gram per deciliter from baseline over a 24-week core period. ENERGIZE-T will evaluate 240 patients randomized 2:1 to 100 milligrams of mitapivat VID or placebo in both beta and alpha thalassemia patients who are regularly transfused, defined as six to 20 RBC units transfused during the 24 weeks prior to randomization.</p> <p class="paywall-full-content invisible no-summary-bullets">The primary endpoint is the percent of patients with a 50% or greater reduction in transfusion burden in any 12-week warming period during the 4eight-week core period. We are in the process of submitting these protocols globally and preparing sites for enrollment. We look forward to initiating both trials by the end of the year.</p> <p class="paywall-full-content invisible no-summary-bullets">Now let's turn to sickle cell disease. Last year, mitapivat was the first PKR activator to demonstrate proof-of-concept in this disease based on initial data from a study being conducted in collaboration with Dr. [indiscernible] of the National Institute of Health.</p> <p class="paywall-full-content invisible no-summary-bullets">And on our last quarterly results call, we provided an update on regulatory feedback to our pivotal plans and unveiled our Phase II/III clinical trial, which we believe minimizes the risk to the approval path for mitapivat in this challenging disease and maximizes the likelihood of a label with a broad indication.</p> <p class="paywall-full-content invisible no-summary-bullets">The operationally seamless Phase II/III study of mitapivat in adults with sickle cell disease will include patients for 16-years of age older, have had between two to 10 sickle cell crises in the past 12-months and have hemoglobin within the range of 5.5 to 10.5 grams per deciliter during screening.</p> <p class="paywall-full-content invisible no-summary-bullets">The Phase II will randomize 69 patients, 1:1:1 to 50 milligrams mitapivat VID, 100 milligrams mitapivat VID or match placebo. The primary endpoint of the hemoglobin response defined as a greater than or equal to one gram per deciliter change from baseline to week 12. And the data will be used to establish a clear dosing paradigm for the Phase III portion.</p> <p class="paywall-full-content invisible no-summary-bullets">The Phase III, which will commence after the Phase II analysis, will randomized 198 patients 2:1 to the selected Phase II dose of mitapivat or matched placebo. The study will have two primary endpoints.</p> <p class="paywall-full-content invisible no-summary-bullets">Hemoglobin response defined as greater than or equal to one gram per deciliter change from baseline to week 52 and the annualized rate of sickle cell pain crises. We are in the process of operationalizing the study and are on-track for initiation by the end of the year.</p> <p class="paywall-full-content invisible no-summary-bullets">In addition, we continue to work with our collaborators at the NIH and the University of Utrecht on their studies of mitapivat in sickle cell disease. Data from both studies are expected at medical meetings later this year. At the NIH, Dr. Chen has completed enrollment in the core study with 17 patients and continues to enroll into the extension study.</p> <p class="paywall-full-content invisible no-summary-bullets">In support of our hypothesis that mitapivat has the potential to be a novel therapy for patients with sickle cell disease, I'm pleased to share that in collaboration with the investigators from the University Medical Center in The Netherlands, we recently published a manuscript in Blood investigating the ex vivo effect of mitapivat on red blood cells from patients with sickle cell disease and healthy controls.</p> <p class="paywall-full-content invisible no-summary-bullets">Red blood cells isolated from patients with sickle cell disease showed reduced pyruvate kinase activity compared to controls due to decreased stability of PKR. Treatment of isolated sickle cell red blood cells with mitapivat restored pyruvate kinase activity, leading to a reduction in 23 bpg and cell sickling behavior.</p> <p class="paywall-full-content invisible no-summary-bullets">The publication is important because, first, it suggests a compromised red blood cell metabolism may contribute to the complex pathophysiology of sickle cell disease; and second, it provides mechanistic support for mitapivat as a potential novel therapy for sickle cell disease.</p> <p class="paywall-full-content invisible no-summary-bullets">Beyond mitapivat, we are also advancing our next-generation PKR activator, AG946, through a Phase I healthy volunteer study. The trial began enrolling last fall, and we expect to submit data from it for presentation at a medical meeting by the end of the year. Our analysis of the totality of the AG946 healthy volunteer data will inform next steps for the clinical development of this molecule.</p> <p class="paywall-full-content invisible no-summary-bullets">With that, I will turn it over to Darrin to discuss our commercial activities.</p> <p class="paywall-full-content invisible no-summary-bullets"><strong>Darrin Miles</strong></p> <p class="paywall-full-content invisible no-summary-bullets">Thank you, Chris. Today, I will first briefly review consumer performance for Q1, which is the last period for which Agios is accountable for sales of the product. I will then summarize our progress on cross-functional launch preparedness in anticipation of the potential approval of mitapivat in 2022.</p> <p class="paywall-full-content invisible no-summary-bullets">TIBSOVO net sales in Q1 reached $37 million, largely driven by market increases in utilization across newly diagnosed and relapsed/refractory AML, partially offset by higher expenses related to Q1 Part D coverage gap seasonality and increased volume moving through the 40B institutions.</p> <p class="paywall-full-content invisible no-summary-bullets">Turning to mitapivat launch readiness. The team made progress on a number of fronts, including PK deficiency education, physician and patient profiling and the ongoing field in build. In November, we have announced the launch of the Anemia ID program, a partnership with Perkinelmer to offer free genetic testing to help patients and physicians reach a definitive diagnosis for patients with suspected hereditary anemia.</p> <p class="paywall-full-content invisible no-summary-bullets">The program has been well received and is increasingly utilized to help patients with their diagnosis by simplifying the testing requirements attended with reaching a definitive diagnosis of a patient's hemolytic anemia.</p> <p class="paywall-full-content invisible no-summary-bullets">The program also provides Agios with the identified patient level information, which adds meaningfully to our understanding of the PK deficiency patient profile. Our experience with this program highlights the magnitude of unmet need in the community and the deepening sense of urgency to improve the diagnosis of patients with hemolytic anemias, like PK deficiency.</p> <p class="paywall-full-content invisible no-summary-bullets">As Jackie mentioned, in March, 23 &amp; Me added a new PK deficiency carrier status report to their library of genetic insights and tools. Members who are either carriers are homozygous for the R486W variant and the PKLR gene, the most common Southern European PKR variant, are invited to receive the customized report with more information regarding their risk of developing PK deficiency and additional resources.</p> <p class="paywall-full-content invisible no-summary-bullets">The report included a summary of signs and symptoms of PK deficiency and other relevant clinical and genetic information. We expect that a number of patients who are carriers will seek genetic counseling for more robust testing, potentially through Anemia ID and other mechanisms resulting in a definitive diagnosis.</p> <p class="paywall-full-content invisible no-summary-bullets">We have also made good progress in expanding our ability to provide important information about PK deficiency to patients with questions. We intend to launch a robust PK deficiency patient education program by the end of the quarter, administered through existing Agios infrastructure, MyAgios Patient Support.</p> <p class="paywall-full-content invisible no-summary-bullets">The program will invite patients to open to routine communications with trained staff-related to information about their disease. The launch of the expanded patient education program coincides with the expected completion of the build of our customer-facing field organization before the end of Q2. The modest-sized field team will include hemolytic anemia specialists and skilled clinical educators.</p> <p class="paywall-full-content invisible no-summary-bullets">These roles are essential for accelerating our understanding of physicians treating PK deficiency, the profiles of the patients they are treating and our disease education efforts via virtual and increasingly face-to-face interactions as we head into the second half of the year.</p> <p class="paywall-full-content invisible no-summary-bullets">These efforts, along with the anticipated approval of a PK deficiency specific ICD-10 code by the end of the year, will substantially accelerate understanding of the number and profile of patients being diagnosed with PK deficiency today. Overall, launch preparedness is on-track, and we are pleased with progress to date.</p> <p class="paywall-full-content invisible no-summary-bullets">I will now turn it over to Jonathan to cover Q1 financials.</p> <p class="paywall-full-content invisible no-summary-bullets"><strong>Jonathan Biller</strong></p> <p class="paywall-full-content invisible no-summary-bullets">Thanks, Darrin. Our first quarter 2021 financial results can be found in the press release we issued this morning, which I will summarize. More detail will be included in our 10-Q filing later today.</p> <p class="paywall-full-content invisible no-summary-bullets">As Jackie mentioned, the sale of the Oncology business to Servier closed on March 31<sup>st</sup>, and as a result, the first quarter results related to our oncology business can be found in the discontinued operations note to our financial statements.</p> <p class="paywall-full-content invisible no-summary-bullets">I will first address our continuing operations for the business. Research and development for the first quarter was $57.7 million, an increase of $2.3 million compared to the first quarter of 2020. The modest year-over-year increase in R&amp;D was driven primarily by start-up costs associated with the Phase III studies of mitapivat in thalassemia and sickle cell disease.</p> <p class="paywall-full-content invisible no-summary-bullets">Selling, general and administrative expenses for continuing operations were $33.1 million for the first quarter, representing a $1.5 million increase over first quarter of 2020. The increase in SG&amp;A expense was primarily due to certain onetime workforce expenses.</p> <p class="paywall-full-content invisible no-summary-bullets">For our discontinued operations, total revenue for the first quarter was $41.4 million, which included $37 million of net sales of TIBSOVO. Also included in discontinued operations is $50.2 million of operating expenses that were primarily attributable to professional fees and workforce expenses directly related to the Servier transaction.</p> <p class="paywall-full-content invisible no-summary-bullets">We ended the quarter with cash, cash equivalents and marketable securities of $2.4 billion. We expect that this cash balance, together with anticipated interest income, future product sales of mitapivat and royalties on TIBSOVO will fund our current operating plan through major catalysts and to cash flow positivity without the need to raise additional equity.</p> <p class="paywall-full-content invisible no-summary-bullets">As previously disclosed, our Board of Directors authorized the repurchase of up to $1.2 billion of our outstanding shares using the proceeds from the sale of the Oncology business. And earlier this month, we closed the repurchase of the approximately 7.1 million shares of Agiosâ€™ common stock held by BMS and its affiliates for an aggregate purchase price of $344.5 million or $48.38 per share.</p> <p class="paywall-full-content invisible no-summary-bullets">In addition, we have put in place a 10b5-1 plan designed to efficiently repurchase a meaningful portion of the remaining shares by year-end. As is customary, we will report on repurchases made pursuant to these plans and any open market or privately negotiated repurchases in our future quarterly earnings reports.</p> <p class="paywall-full-content invisible no-summary-bullets">With that, operator, please open the line for questions.</p> <p id="question-answer-session" class="paywall-full-content invisible no-summary-bullets"><strong>Question-and-Answer Session</strong></p> <p class="paywall-full-content invisible no-summary-bullets"><strong>Operator</strong></p> <p class="paywall-full-content invisible no-summary-bullets">Thank you. [Operator Instructions] Our first question comes from Alethia Young with Cantor.</p> <p class="paywall-full-content invisible no-summary-bullets"><strong><span class="question">Alethia Young</span></strong></p> <p class="paywall-full-content invisible no-summary-bullets">Congrats on all the progress. I just wanted to talk a little bit about maybe potential pipeline or indication expansion for both mitapivat and potentially 946, just kind of how you are thinking about some of the potential new indications that you might be moving forward with based on what you know about the biology here. Thanks.</p> <p class="paywall-full-content invisible no-summary-bullets"><strong><span class="answer">Christopher Bowden</span></strong></p> <p class="paywall-full-content invisible no-summary-bullets">Alethia, it is Chris Bowden here. We think about pyruvate kinase in two ways at this point. There is a PKR part of it, and I spoke in my - and you are familiar with the advanced stage programs, where we are going after registration in pyruvate kinase deficiency, thalassemia and sickle cell disease.</p> <p class="paywall-full-content invisible no-summary-bullets">There are a couple of other indications that we are thinking about where we can approach pyruvate kinase from activating wild type. And there is a number of them, including hereditary spherocytosis. We have some interest in myelodysplastic syndrome.</p> <p class="paywall-full-content invisible no-summary-bullets">The anemia of myelodysplastic syndrome can potentially be addressed through the activation of wild-type PKR, again, addressing and improving the red cell health. And then we have been talking about the potential for activating PKM2 as opening up a number of doors and some other indications.</p> <p class="paywall-full-content invisible no-summary-bullets">Why don't I stop at that point and let Bruce Car, who is on the call with us today talk a little bit about PKM2, and we are looking forward to the second half of the year and opening that up a little more at Research Day. But Bruce, why don't you provide a little more color, please.</p> <p class="paywall-full-content invisible no-summary-bullets"><strong><span class="answer">Bruce Car</span></strong></p> <p class="paywall-full-content invisible no-summary-bullets">Yes. Thanks very much, Chris. So just by analogy, PKR is deficient - of course, in PK deficiency in red cells and it is relatively deficient in many different hemolytic anemias. When one looks at the tissues that express PKM 2, its generation of ATP and function is abnormally in many disease states as well.</p> <p class="paywall-full-content invisible no-summary-bullets">So since early last year, we have been studying the tissue distribution and the involvement of PKM two in a variety of different disease processes. Based on that work, we have then identified several likely indications for PKN 2. And they are really quite broad, depending on the place it is expressed.</p> <p class="paywall-full-content invisible no-summary-bullets">It is expressed in the brain, in the retina, in regenerating muscle and many other tissues, in the gut wall. We have been conducting appropriate nonclinical models to evaluate the potential for these disease indications, and we are actually just starting to get some very promising data in recent months, suggesting the indications that we could possibly go into in, many of which would, of course, require on partnering well outside of our hematology expertise.</p> <p class="paywall-full-content invisible no-summary-bullets">And we hope to be able to talk about these indications perhaps sometime later in the third quarter at an R&amp;D Day. But the work is going very well at the moment, and some of these indications are actually yielding spectacular nonclinical results to the extent we understand a translatable. We are not sure yet, but a lot of promise for any additional indication for PKM 2.</p> <p class="paywall-full-content invisible no-summary-bullets"><strong><span class="question">Alethia Young</span></strong></p> <p class="paywall-full-content invisible no-summary-bullets">That is helpful. Thank you very much.</p> <p class="paywall-full-content invisible no-summary-bullets"><strong>Operator</strong></p> <p class="paywall-full-content invisible no-summary-bullets">Thank you. Our next question comes from Mohit Bansal with Citigroup. Your line is open.</p> <p class="paywall-full-content invisible no-summary-bullets"><strong><span class="question">Mohit Bansal</span></strong></p> <p class="paywall-full-content invisible no-summary-bullets">Thanks for taking my questions, congrats on the project. A couple of questions from my side. One is regarding the pricing, I may sound like a book of record because I have asked it in the past as well. But given you would be launching in an ultra-rare indication like PKD, how are you thinking about pricing right now because more rare indication like sickle cell is still not probably like four-years away, four-years after the PKD indication. And I will pause here.</p> <p class="paywall-full-content invisible no-summary-bullets"><strong><span class="answer">Darrin Miles</span></strong></p> <p class="paywall-full-content invisible no-summary-bullets">This is Darren. No booking record at all. Happy to address any questions on pricing. Now I won't tell you the pricing that we are thinking about. But I can give you some indications of how we are thinking about it, right.</p> <p class="paywall-full-content invisible no-summary-bullets">So as you know, it is an ultra orphan indication. We are going to price in a way that reflects the clinical value, particularly now that we have seen both of the Phase III studies, but we are pricing the way that represents or reflects the clinical value for this patient population.</p> <p class="paywall-full-content invisible no-summary-bullets">As we have shared in the past, our takeaway from engagements with the payer community is that we believe that, that pricing should also extend to thalassemia. Going to sickle cell, you have a different payer mix, a different mix of patient population and associated payer mix change as well.</p> <p class="paywall-full-content invisible no-summary-bullets">So there is the potential that we would adjust price for the sickle cell market. But right now, we think the price that we launched with -- at for PKD will carry over a well into fall, and then we will revisit as we go into super cell.</p> <p class="paywall-full-content invisible no-summary-bullets"><strong><span class="answer">Jacqualyn Fouse</span></strong></p> <p class="paywall-full-content invisible no-summary-bullets">Just add one thing Mohit, it is Jackie. As Darrin alluded to, I think we will also price for sickle cell based on the totality of the clinical data from the pivotal program for sickle cell. So we will need to see what that yields in terms of both of the endpoints that we have built into that program.</p> <p class="paywall-full-content invisible no-summary-bullets"><strong><span class="question">Mohit Bansal</span></strong></p> <p class="paywall-full-content invisible no-summary-bullets">Very helpful and one more question I may, probably for Jackie again. So given that, I mean, your strong balance sheet and even in the buyback plan, it leave a lot of cash on hand. So when you look at your pipeline and cash at hand, do you think you could look at the external opportunities as well or do you think you have enough on your plate right now with the preclinical and the clinical programs right now?</p> <p class="paywall-full-content invisible no-summary-bullets"><strong><span class="answer">Jacqualyn Fouse</span></strong></p> <p class="paywall-full-content invisible no-summary-bullets">So I think one of the things that is most exciting about where we are as we start the next chapter in our Agios life, it is the number of things that we have in the pipeline and some of the opportunities that Bruce alluded to, where I think that we are going to start to see support for those and where we might be able to go with them, including also the indications that Chris highlighted for potentially mitapivat, 946, where you could move quite quickly into the clinic.</p> <p class="paywall-full-content invisible no-summary-bullets">So we have a ton of things that we wholly own, we know the chemical matter very well and the biology and everything else. So those are our top priorities for the moment. That being said, we do keep our eyes on other things that are out there, and we don't want to miss anything that might be complementary or relevant for us. And we always do that and we will continue to do that.</p> <p class="paywall-full-content invisible no-summary-bullets">So it is not out of the realm of possibility that we might do something on the early side because that is kind of been what is been in our sweet spot. But we have a ton of things that we think are pretty cool going on right now that are really what we have got the team focused on. Thanks.</p> <p class="paywall-full-content invisible no-summary-bullets"><strong><span class="question">Mohit Bansal</span></strong></p> <p class="paywall-full-content invisible no-summary-bullets">Got it, thank you Jacqualyn, I really appreciate it.</p> <p class="paywall-full-content invisible no-summary-bullets"><strong>Operator</strong></p> <p class="paywall-full-content invisible no-summary-bullets">Thank you. Our next question comes from Peter Lawson with Barclays. Your line is open.</p> <p class="paywall-full-content invisible no-summary-bullets"><strong><span class="question">Peter Lawson</span></strong></p> <p class="paywall-full-content invisible no-summary-bullets">Hey, thanks for taking the questions. Just a question for Jonathan, just on the share repurchase and kind of how quickly you think about doing that, and if you have got a kind of a goal in mind by year-end sort of share count and when that repurchase starts.</p> <p class="paywall-full-content invisible no-summary-bullets"><strong><span class="answer">Jonathan Biller</span></strong></p> <p class="paywall-full-content invisible no-summary-bullets">Sure. Thanks for the question. So as we have talked about, we made a nice start with our share repurchase program, successfully negotiating the repurchase of the 10% stake that Bristol owned. We think we got that at an attractive price.</p> <p class="paywall-full-content invisible no-summary-bullets">And around that same time, we put in plan our own plans to be repurchasing in the market through 10b5-1 plans. And I think we have disclosed the current plan that is in place would buy up to $600 million, and the timing of that depends if we have algorithms and other things in place. So it depends on stock price movements and things like that.</p> <p class="paywall-full-content invisible no-summary-bullets">But we would expect that by the end of the year, we would have, in combination with the Bristol stake, have exceeded half or more of the purchases that repurchases that we intend to make. The exact amount is hard to predict because it does depend to some extent on the volatility that we will see in our stock price and macro volatility as well.</p> <p class="paywall-full-content invisible no-summary-bullets"><strong><span class="question">Peter Lawson</span></strong></p> <p class="paywall-full-content invisible no-summary-bullets">Great. And then just a quick question for Jackie or Chris maybe around. The work with 23 &amp; Me on PK deficiency carrier status. Do you think that was going to help and has that led to any kind of better understanding around both the incidents and prevalence of PKD?</p> <p class="paywall-full-content invisible no-summary-bullets"><strong><span class="answer">Jacqualyn Fouse</span></strong></p> <p class="paywall-full-content invisible no-summary-bullets">Yes. I think Darrin is the best place to answer that. Do you want to jump in, Darrin?</p> <p class="paywall-full-content invisible no-summary-bullets"><strong><span class="answer">Darrin Miles</span></strong></p> <p class="paywall-full-content invisible no-summary-bullets">Yes, sure. Happy to. So yes, I think it adds meaningfully to our understanding of the overall patient's patient profile. It is important to note that the 23andMe chip looks at one variant. It is an important variant, what is most commonly referred to in the literature.</p> <p class="paywall-full-content invisible no-summary-bullets">But if you recall, we got upwards of 300 mutations or so for PKD. So it is while important and it is giving us some very meaningful insights based on the population that have taken the 23andMe tests, certainly, it wouldn't be sufficient, right. So we are looking at multiple sources to be able to help us to better understand the true prevalence of the disease.</p> <p class="paywall-full-content invisible no-summary-bullets">But what we have seen thus far is very encouraging, and at least in the 23andMe data set. And the fact that those patients who then are carriers or are homozygous for the 486 mutation or variant are getting direct information to help them understand then what they should do based on that, right.</p> <p class="paywall-full-content invisible no-summary-bullets">And then we have created additional mechanisms or channels around those patients to help them to be able to pursue additional genetic testing potentially through an Anemia ID. And then eventually, once we launch the Myagios PK or part of the kinase deficiency patient support program by the end of the quarter.</p> <p class="paywall-full-content invisible no-summary-bullets">Potentially, those patients will then opt into our patient support program, which will then allow them to be able to get timely information about their disease and then after approval, access to medicate.</p> <p class="paywall-full-content invisible no-summary-bullets"><strong><span class="question">Peter Lawson</span></strong></p> <p class="paywall-full-content invisible no-summary-bullets">Okay, thank you. Thank you so much for taking the questions.</p> <p class="paywall-full-content invisible no-summary-bullets"><strong>Operator</strong></p> <p class="paywall-full-content invisible no-summary-bullets">Thank you. Our next question comes from Anupam Rama with Jpmorgan. Your line is open.</p> <p class="paywall-full-content invisible no-summary-bullets"><strong><span class="question">Tessa Romero</span></strong></p> <p class="paywall-full-content invisible no-summary-bullets">Good morning guys. This is Tessa on the call for Anupam. Thank you for taking our question. Just one from us. Can you remind us if there are any additional key analyses at EHA in June that we should be looking at specifically around the thalassemia or PKD programs? Thank you so much.</p> <p class="paywall-full-content invisible no-summary-bullets"><strong><span class="answer">Christopher Bowden</span></strong></p> <p class="paywall-full-content invisible no-summary-bullets">Yes. Hi, it is Chris Bowden here. I think that for part of a kinase deficiency, this is the first time that we are that the results from the pivotal studies, ACTIVATE and ACTIVATE-T, will be presented. So I think that the key analyses are multiple. There is of course the primary endpoints, there is the safety.</p> <p class="paywall-full-content invisible no-summary-bullets">I think one really important component of ACTIVATE, it is a randomized trial. So you will - it will be the first time we will be able to see the results - the safety results of mitapivat against a placebo-controlled where both patients and clinicians are blinded.</p> <p class="paywall-full-content invisible no-summary-bullets">So that will give a much better and, I would say, balanced view of what the safety profile looks like over a substantial dosing period. Of course, the patient-reported outcomes as well in a placebo-controlled trial are very important. So there will be multiple components of that that will be important.</p> <p class="paywall-full-content invisible no-summary-bullets">For thalassemia, the build on the previous data that we showed to see how durable those hemoglobin responses look like will be very important because this is another program that we are taking forward into Phase III.</p> <p class="paywall-full-content invisible no-summary-bullets">And since we see made mitapivat as a drug that continues to demonstrate with this safety profile, that it can be given for long periods of time, it is compatible with chronic dosing, that the durability of responses are very important as well.</p> <p class="paywall-full-content invisible no-summary-bullets">I think those are the key components. And there will also be additional data around long-term safety with mitapivat and as well as other descriptions of the disease burden of pyruvate kinase deficiency. So there will be many analyses and the overall picture will be extensive that we will present on mitapivat across those two diseases.</p> <p class="paywall-full-content invisible no-summary-bullets"><strong><span class="question">Tessa Romero</span></strong></p> <p class="paywall-full-content invisible no-summary-bullets">Okay, great. Thanks so much for taking the questions.</p> <p class="paywall-full-content invisible no-summary-bullets"><strong>Operator</strong></p> <p class="paywall-full-content invisible no-summary-bullets">Thank you. Our next question comes from Mark Breidenbach with Oppenheimer. Your line is open.</p> <p class="paywall-full-content invisible no-summary-bullets"><strong><span class="question">Mark Breidenbach</span></strong></p> <p class="paywall-full-content invisible no-summary-bullets">Just on the upcoming readouts from your academic collaborators working in sickle cell disease. I'm wondering if the NIH readout will include results from the extension study or will it more likely focus on the core study period? And also, what can we reasonably expect in terms of the number of efficacy evaluable patients from the Utrecht study? And could you remind us of the main differences between the Utrecht and NIH trials in terms of study design? Thanks for taking the question.</p> <p class="paywall-full-content invisible no-summary-bullets"><strong><span class="answer">Christopher Bowden</span></strong></p> <p class="paywall-full-content invisible no-summary-bullets">Well, I will take the back part first. The NIH study, it is an eight-week dosing period that ranges with eight-week continuous dosing period with the dose escalation build in, starting at five milligrams to 20 to 50 to 100 in, and then there is a taper and then patients are eligible to go into an extension study.</p> <p class="paywall-full-content invisible no-summary-bullets">The Utrecht study is enrolling up to 10 patients and they started 20, then they go to 50 and they get 100 and they stay on with chronic dosing. So I think those are the major differences. Overall, the patient populations from an trial eligibility criteria are roughly comparable.</p> <p class="paywall-full-content invisible no-summary-bullets">So now your question around what will be presented by the NIH is still up in the air, and I think that depends on - it will really depend on how many patients come into the extension, how much follow-up they have at the time of when they perform their data cut in order to prepare for whatever meeting they are going to submit this to.</p> <p class="paywall-full-content invisible no-summary-bullets">I will just remind you, this is an investigator-sponsored study, so they hold the IND and are the primary decision-maker on those issues. We collaborate with them, and things are going really well. But at this point, they haven't really gotten around to thinking through that level of detail. In terms of overall evaluable patients from the Utrecht study, the way that protocol is written is that they are going to be looking for at least up to 10, I should say.</p> <p class="paywall-full-content invisible no-summary-bullets"><strong><span class="question">Mark Breidenbach</span></strong></p> <p class="paywall-full-content invisible no-summary-bullets">Okay, got it. And very quickly on thalassemia, I'm wondering if you can tell us what the planned distribution is between European versus U.S. clinical sites in the ENERGIZE trials and to what extent is COVID creating an obstacle for opening clinical sites, especially in Europe right now?</p> <p class="paywall-full-content invisible no-summary-bullets"><strong><span class="answer">Christopher Bowden</span></strong></p> <p class="paywall-full-content invisible no-summary-bullets">So we will be able to provide a site list, and we will do that in the trials in progress type session or something like that. So that information will be forthcoming. At this point, we are not running into any turbulence with activating the study and getting it up and running with regards to the pandemic. However, that is something that we really keep our close eye on because things can change very rapidly. But no problems as of this juncture, I'm knocking on my desk wood here.</p> <p class="paywall-full-content invisible no-summary-bullets"><strong><span class="question">Mark Breidenbach</span></strong></p> <p class="paywall-full-content invisible no-summary-bullets">Alright, sounds good. Thanks for taking the questions.</p> <p class="paywall-full-content invisible no-summary-bullets"><strong>Operator</strong></p> <p class="paywall-full-content invisible no-summary-bullets">Our next question comes from Michael Schmidt with Guggenheim Securities.</p> <p class="paywall-full-content invisible no-summary-bullets"><strong><span class="question">Kelsey Goodwin</span></strong></p> <p class="paywall-full-content invisible no-summary-bullets">It is Kelsey on for Michael. We had a couple on mitapivat in PKD. I guess now that we are almost, I guess, about a year out from launch, I guess, how are you thinking about the speed of uptake and how maybe the education efforts might accelerate this? And then have you been able to get any initial feedback from physicians on the data so far, maybe just that presented in the top line press releases?</p> <p class="paywall-full-content invisible no-summary-bullets"><strong><span class="answer">Darrin Miles</span></strong></p> <p class="paywall-full-content invisible no-summary-bullets">Got you. Darin here. So yes, so we are about a year out from approval, and so we have been building - expanding the team in order to be able to get a lead on -- get ahead on all of patient profiling, physician profiling efforts, right, which ultimately will help with help with uptake post approval. So as I mentioned, we have hired the full sales team. We expect them to be trained and then out in the field by the end of the quarter.</p> <p class="paywall-full-content invisible no-summary-bullets">So we have also added some clinical educators. We will also engage with practices to help them with understanding - increasing overall awareness and understanding of the disease. That is on top of the expanded patient finding efforts, all of which will help us to ensure that we are we have got a good understanding of the overall market, including the number of potential diagnosed patients by the time we get through approval, and then we will continue those efforts through approval.</p> <p class="paywall-full-content invisible no-summary-bullets">When it comes to uptake post-approval, obviously, those patients that are identified - or those physicians who have patients that are identified will be at top of the list in terms of promotional efforts by the team. The key regulator on uptake is going to be, obviously, physician inclination to prescribe, but also payer management, right.</p> <p class="paywall-full-content invisible no-summary-bullets">And so it will take a few months for policies to be written. So that is important but doesn't necessarily have to be an obstacle for adoption. It just may require physicians, before payers fully adopted a policy or crafted a policy, to seek - to get involved in terms of helping patients to be able to get access. But that is not unusual. That is customary in all approvals.</p> <p class="paywall-full-content invisible no-summary-bullets">In terms of early physician response to the data set, we have been working with anonymized data to be able to get some physician and payer reaction to the overall profile, which has been quite encouraging for us. It is mostly consistent with what we have seen or heard from the community when we were using just the target profile data.</p> <p class="paywall-full-content invisible no-summary-bullets">But actually, what we see in terms of responses, the overall profile of the patient population as well as the PRO, quality of life data, it actually is even more encouraging in many respects on what we have heard before. So I think all in all, we are in good shape, leading up to the approval and being able to raise all awareness and enthusiasm for prescribing mitapivat once we get through approval.</p> <p class="paywall-full-content invisible no-summary-bullets"><strong><span class="question">Kelsey Goodwin</span></strong></p> <p class="paywall-full-content invisible no-summary-bullets">Great, that is super helpful. Thank you so much.</p> <p class="paywall-full-content invisible no-summary-bullets"><strong>Operator</strong></p> <p class="paywall-full-content invisible no-summary-bullets">Thank you. Our next question comes from Salveen Richter with Goldman Sachs. Your line is open.</p> <p class="paywall-full-content invisible no-summary-bullets"><strong><span class="question">Unidentified Analyst</span></strong></p> <p class="paywall-full-content invisible no-summary-bullets">This is Elizabeth on for Salveen. Regarding the Anemia ID program, just wondering how many indications that might open up for you? And then are you thinking of pursuing similar programs to the 23andme initiative for other rare indications and potentially expanding for other variants of PKD?</p> <p class="paywall-full-content invisible no-summary-bullets"><strong><span class="answer">Darrin Miles</span></strong></p> <p class="paywall-full-content invisible no-summary-bullets">Sure. So this is Darrin here. I will address this first. For Anemia ID as well as 23andMe, they are both focused on helping us to improve our understanding of PKD specifically. So though in Anemia ID, the panel that is used can help a physician to identify any number of hemolytic anemias, what we are focused on is those data associated with pyruvate kinase deficiency and seeing the 23andMe.</p> <p class="paywall-full-content invisible no-summary-bullets">Now we haven't yet discussed how those programs may be helpful as we look ahead to the expanded indications for mitapivat. But given what we have observed with the program this fall, I think the success we are having with PKD, I would say that those are probably viable options for us for the additional indications as well.</p> <p class="paywall-full-content invisible no-summary-bullets"><strong><span class="question">Unidentified Analyst</span></strong></p> <p class="paywall-full-content invisible no-summary-bullets">Thank you.</p> <p class="paywall-full-content invisible no-summary-bullets"><strong>Operator</strong></p> <p class="paywall-full-content invisible no-summary-bullets">Thank you. Our next question comes from Marc Frahm with Cowen &amp; Company. Your line is open.</p> <p class="paywall-full-content invisible no-summary-bullets"><strong><span class="question">Unidentified Analyst</span></strong></p> <p class="paywall-full-content invisible no-summary-bullets">Hi this is [indiscernible] for Mark. I have a follow-up question to your earlier comments regarding the thalassemia data that we presented at EHA. In terms of - would the data set be large enough to be a long enough follow-up to start capturing the impact of the improved hemoglobin level? And then second question regarding the ENERGIZE trials, how long do you expect enrollment to take? And should we expect both trials to be on a similar time line or is one likely to take less time to complete besides the fact that they have different and for enrollment?</p> <p class="paywall-full-content invisible no-summary-bullets"><strong><span class="answer">Christopher Bowden</span></strong></p> <p class="paywall-full-content invisible no-summary-bullets">Yes. It is Chris here. Thank you for your question. Our initial presentation of the data that [indiscernible] gave at EHA last year, I think illustrated what we defined as proof of clinical concept, where we saw the majority of patients having a greater than one gram per deciliter increase.</p> <p class="paywall-full-content invisible no-summary-bullets">So I think one of the important findings in this presentation is now, a year later, with 20 patients accrued with longer-term follow-up, the durability of those responses and the safety will be a very important part of that presentation.</p> <p class="paywall-full-content invisible no-summary-bullets">Now with regards to the time lines, the time lines of accrual of one trial versus the other. It is too early for us to guide to that, but I can refer you to the slide that we presented today, where our first goal - our most immediate goal is initiating both of these studies in the second half of this year. And we are very much on-track to do so with anticipated approvals in the 2025 time frame.</p> <p class="paywall-full-content invisible no-summary-bullets">So we will be able to provide more details as things go along. And right now, we are just entering into the, what I call the second stage of the operations, that is we are beyond the beginning of the beginning and now we are getting into IRBs, dealing with sites and all that.</p> <p class="paywall-full-content invisible no-summary-bullets">So it is too early for us to guide to one trial finishing - the timing of one versus the other. We very much set our timelines based on detailed feasibility and then, of course, track things along the way.</p> <p class="paywall-full-content invisible no-summary-bullets">And if we see important movements in either direction, things going faster or slower, then it is our job to talk about that once we are very confident of it and what the implications are. But right now, we are very encouraged by how we are tracking in terms of starting the study and sticking with our anticipated approval guidance of 2025.</p> <p class="paywall-full-content invisible no-summary-bullets"><strong><span class="question">Unidentified Analyst</span></strong></p> <p class="paywall-full-content invisible no-summary-bullets">Okay, thank you for taking the call.</p> <p class="paywall-full-content invisible no-summary-bullets"><strong>Operator</strong></p> <p class="paywall-full-content invisible no-summary-bullets">Thank you. And I'm currently showing no further questions at this time. I would like to turn the call back over to Jackie Fouse for closing remarks.</p> <p class="paywall-full-content invisible no-summary-bullets"><strong>Jacqualyn Fouse</strong></p> <p class="paywall-full-content invisible no-summary-bullets">Thank you operator, I'm very excited about the progress we have made so far this year, including the transition of our Oncology business to Servier. We look forward to making a meaningful difference in the lives of patients with diseases that lie within our focus areas as we move into our future as a transformed Agios, starting with PK deficiency.</p> <p class="paywall-full-content invisible no-summary-bullets">To close, I would like to thank my Agios colleagues for their dedication and passion for making a difference for patients. I also want to thank all of the patients, caregivers and physicians who participate in our clinical trials. Without them, we could not do what we do. And thank all of you for joining us today. Take care.</p> <p class="paywall-full-content invisible no-summary-bullets"><strong>Operator</strong></p> <p class="paywall-full-content invisible no-summary-bullets">This concludes today's conference call. Thank you for participating. You may now disconnect.</p></div><div class="above_now_read-piano-placeholder"></div><div><ul><li class="ja_E2" data-test-id="analysis-and-news-bullet">Read more current<!-- --> <!-- -->AGIO<!-- --> <a class="J_0 t_ej t_ek t_ep N_L N_gy" href="/symbol/AGIO"><span class="">analysis and news</span></a></li><li class="ja_E2" data-test-id="earnings-call-transcripts-bullet">View all<!-- --> <a class="J_0 t_ej t_ek t_ep N_L N_gy" href="/earnings/earnings-call-transcripts"><span class="">earnings call transcripts</span></a></li></ul></div></div></div></div><div class="piano-paywall-container"></div><div></div><footer class="nd_J t_ei t_es aP_i9 paywall-full-content" data-test-id="post-footer"><span class="ne_L ne_K5 t_ei t_ek s_am s_bq s_aw s_aU"><button class="uE_BS rI_Rx t_ei t_ek uE_jc" data-test-id="like-button" type="button"><svg viewBox="0 0 19 16" xmlns="http://www.w3.org/2000/svg" class="uE_fv"><path d="M17.8 7.18h-2.69V15h2.69zm-4.86 6.4s.1 1.32-1.34 1.32H4.26s-1.86-2.13-3.2-6.7C.64 6.78 2.7 6.57 2.7 6.57h5.17S5.9 4.04 5.7 2.21C5.5.38 7.26.69 8.39 2.71c1.14 2.04 4.55 3.86 4.55 3.86v7z"></path></svg><span class="uE_iM">Like</span></button></span><button aria-expanded="false" aria-label="Share options" class="flex shrink-0 items-center justify-center text-large-r text-black-35 dark:text-black-10" data-test-id="custom-share-button" type="button"><span class="truncate"><span class="ne_L ne_K5 t_ei t_ek s_am s_bq s_aw s_aU"><svg viewBox="0 0 18 18" xmlns="http://www.w3.org/2000/svg" class="ne_fv"><path d="M14.8 17.14a2.7 2.7 0 0 1-2.13-2.7l.01-.3-3.88-1.73-3.97-1.77c-.07-.03-.11 0-.3.17a2.67 2.67 0 1 1 0-3.83l.23.23 3.96-1.77 3.96-1.76-.01-.3c-.04-.7.24-1.44.74-1.97.64-.67 1.7-.96 2.6-.72A2.73 2.73 0 0 1 18 3.13a2.67 2.67 0 0 1-4.56 2.02l-.19-.18L9.3 6.73 5.33 8.5v.83l3.94 1.75 3.95 1.76.24-.22a2.67 2.67 0 1 1 1.35 4.52z"></path></svg><span class="ne_iM s_cs">Share</span></span></span></button><button aria-expanded="false" aria-label="Print options" class="flex shrink-0 items-center justify-center text-large-r text-black-35 dark:text-black-10" data-test-id="print-dropdown" type="button"><span class="truncate"><span class="ne_L ne_K5 t_ei t_ek s_am s_bq s_aw s_aU"><svg viewBox="0 0 14 13" xmlns="http://www.w3.org/2000/svg" class="ne_fv"><path d="M11.2 0H2.8v2.8h8.4V0zM0 3.5v6.3h2.8v2.8h8.4V9.8H14V3.5H0zm9.8 7.7H4.2V7.7h5.6v3.5zm2.48-4.93h-1.4v-1.4h1.4v1.4z"></path></svg><span class="ne_iM s_cs">Print</span></span></span></button><a class="ne_L ne_K5 t_ei t_ek s_am s_bq s_aw s_aU nd_K0" data-test-id="comment-button" href="/article/4422482-agios-pharmaceuticals-inc-agio-ceo-jacqualyn-fouse-on-q1-2021-results-earnings-call#comments"><svg viewBox="0 0 16 15" xmlns="http://www.w3.org/2000/svg" class="ne_fv nd_K4"><path d="M7.04 12.28a8.8 8.8 0 0 1-4.6 2.21.79.79 0 0 1-.63-.2.91.91 0 0 1-.28-.45.61.61 0 0 1-.01-.4c0 .03-.01.04 0 .07-.03-.14.01-.21.1-.37l.08-.12.06-.07.05-.07.04-.04.23-.28.27-.32a4.07 4.07 0 0 0 .7-1.37 6.3 6.3 0 0 1-1.76-1.8 4.84 4.84 0 0 1-.17-5c.4-.73.94-1.36 1.62-1.88A7.87 7.87 0 0 1 5.12.95a9.23 9.23 0 0 1 6.6.32 6.87 6.87 0 0 1 2.74 2.12 4.93 4.93 0 0 1 0 6.05c-.68.9-1.6 1.6-2.74 2.12a8.97 8.97 0 0 1-4.68.72z" fill="none"></path></svg><span class="ne_iM s_cs">Comment</span></a></footer></div></div></div></section><!--$--><section class="mx-auto flex w-full flex-col justify-between bg-white dark:bg-black-95 pt-24 md:pt-12 pb-24 px-safe-offset-18 md:pb-20 md:px-safe-or-24 mb-8 md:mb-18 print:hidden" data-test-id="recommended-section"><div class="flex flex-col flex-wrap print:block"><div class="w-full max-w-full"><div class="paywall-full-content"><div class="w-full pb-6 pt-24 md:pb-10 md:pt-20"><div class="-mx-12 -my-4 flex flex-grow items-center flex-wrap"><div class="mr-auto flex flex-shrink flex-grow-0 px-12 py-4"><h4 class="m-0 inline-block text-5x-large-r text-black-35 dark:text-black-30 md:text-4x-large-r" data-test-id="recommended-for-you-card-title">Recommended For You</h4></div></div></div><div data-test-id="recommended-for-you-card-body"><article class="gL_gW fE_gW t_ei s_aw s_aU kM_Ig s_ak s_bo kM_Ig s_ak s_bo kM_Ik kM_Ik gL_z8" data-test-id="post-list-item"><div class="mr-18"><div class="lq_a t_ei t_ek t_ep" data-test-id="user-pic"><svg data-test-id="sprite-icon" class="lq_py lq_gi"><use xlink:href="#alpha"></use></svg></div></div><div><div class="iH_vW t_ei iH_Ek"><div class="iH_Ep"><h3 class="iH_Y s_9 t_eC iH_x6 aW_jn aW_jB aW_jR iH_Em s_dE"><a data-test-id="post-list-item-title" class="iH_L" href="/article/4644068-my-oh-my-2-strong-buys-residential-reits-that-help-me-sleep-well-at-night">My Oh My, 2 Strong Buys: Residential REITs That Help Me Sleep Well At Night</a></h3><footer class="kz_J aW_jl aW_jB aW_jQ" data-test-id="post-footer"></footer></div></div></div></article><article class="gL_gW fE_gW t_ei s_aw s_aU kM_Ig s_ak s_bo kM_Ig s_ak s_bo kM_Ik kM_Ik gL_z8" data-test-id="post-list-item"><div class="mr-18"><div class="flex shrink-0 items-center justify-center relative w-36 h-36 rounded-full" data-test-id="user-pic-wrapper"><img alt="Christopher Robb profile picture" class="dark:text-black-100 flex w-full items-center justify-center overflow-hidden bg-white-96 text-white-96 dark:bg-black-30 rounded-full h-full" data-test-id="user-pic" height="36" loading="lazy" src="https://static3.seekingalpha.com/images/users_profile/051/445/267/big_pic.png" width="36"></div></div><div><div class="iH_vW t_ei iH_Ek"><div class="iH_Ep"><h3 class="iH_Y s_9 t_eC iH_x6 aW_jn aW_jB aW_jR iH_Em s_dE"><a data-test-id="post-list-item-title" class="iH_L" href="/article/4644604-the-fed-is-done-hiking-and-the-holidays-are-about-to-begin">The Fed Is Done Hiking, And The Holidays Are About To Begin</a></h3><footer class="kz_J aW_jl aW_jB aW_jQ" data-test-id="post-footer"><span class="oh_Ji" data-test-id="post-list-author">Christopher Robb</span></footer></div></div></div></article><article class="gL_gW fE_gW t_ei s_aw s_aU kM_Ig s_ak s_bo kM_Ig s_ak s_bo kM_Ik kM_Ik gL_z8" data-test-id="post-list-item"><div class="mr-18"><div class="flex shrink-0 items-center justify-center relative w-36 h-36 rounded-full" data-test-id="user-pic-wrapper"><img alt="Avi Gilburt profile picture" class="dark:text-black-100 flex w-full items-center justify-center overflow-hidden bg-white-96 text-white-96 dark:bg-black-30 rounded-full h-full" data-test-id="user-pic" height="36" loading="lazy" src="https://static1.seekingalpha.com/images/users_profile/000/876/837/big_pic.png" width="36"></div></div><div><div class="iH_vW t_ei iH_Ek"><div class="iH_Ep"><h3 class="iH_Y s_9 t_eC iH_x6 aW_jn aW_jB aW_jR iH_Em s_dE"><a data-test-id="post-list-item-title" class="iH_L" href="/article/4643909-wells-fargo-is-developing-a-big-problem">Wells Fargo Is Developing A Big Problem</a></h3><footer class="kz_J aW_jl aW_jB aW_jQ" data-test-id="post-footer"><span class="oh_Ji" data-test-id="post-list-author">Avi Gilburt</span></footer></div></div></div></article><article class="gL_gW fE_gW t_ei s_aw s_aU kM_Ig s_ak s_bo kM_Ig s_ak s_bo kM_Ik kM_Ik gL_z8" data-test-id="post-list-item"><div class="mr-18"><div class="flex shrink-0 items-center justify-center relative w-36 h-36 rounded-full" data-test-id="user-pic-wrapper"><img alt="Lawrence Fuller profile picture" class="dark:text-black-100 flex w-full items-center justify-center overflow-hidden bg-white-96 text-white-96 dark:bg-black-30 rounded-full h-full" data-test-id="user-pic" height="36" loading="lazy" src="https://static1.seekingalpha.com/images/users_profile/007/375/661/big_pic.png" width="36"></div></div><div><div class="iH_vW t_ei iH_Ek"><div class="iH_Ep"><h3 class="iH_Y s_9 t_eC iH_x6 aW_jn aW_jB aW_jR iH_Em s_dE"><a data-test-id="post-list-item-title" class="iH_L" href="/article/4637656-sell-everything">Sell Everything</a></h3><footer class="kz_J aW_jl aW_jB aW_jQ" data-test-id="post-footer"><span class="oh_Ji" data-test-id="post-list-author">Lawrence Fuller</span></footer></div></div></div></article><article class="gL_gW fE_gW t_ei s_aw s_aU kM_Ig s_ak s_bo kM_Ig s_ak s_bo kM_Ik kM_Ik gL_z8" data-test-id="post-list-item"><div class="mr-18"><div class="flex shrink-0 items-center justify-center relative w-36 h-36 rounded-full" data-test-id="user-pic-wrapper"><img alt="Rida Morwa profile picture" class="dark:text-black-100 flex w-full items-center justify-center overflow-hidden bg-white-96 text-white-96 dark:bg-black-30 rounded-full h-full" data-test-id="user-pic" height="36" loading="lazy" src="https://static.seekingalpha.com/images/users_profile/000/016/392/big_pic.png" width="36"></div></div><div><div class="iH_vW t_ei iH_Ek"><div class="iH_Ep"><h3 class="iH_Y s_9 t_eC iH_x6 aW_jn aW_jB aW_jR iH_Em s_dE"><a data-test-id="post-list-item-title" class="iH_L" href="/article/4643833-the-big-short-eisman-says-buy-bonds-and-old-economy-stocks">The 'Big Short' Eisman Says Buy Bonds And Old Economy Stocks</a></h3><footer class="kz_J aW_jl aW_jB aW_jQ" data-test-id="post-footer"><span class="oh_Ji" data-test-id="post-list-author">Rida Morwa</span></footer></div></div></div></article><article class="gL_gW fE_gW t_ei s_aw s_aU kM_Ig s_ak s_bo kM_Ig s_ak s_bo kM_Ik kM_Ik gL_z8" data-test-id="post-list-item"><div class="mr-18"><div class="lq_a t_ei t_ek t_ep" data-test-id="user-pic"><svg data-test-id="sprite-icon" class="lq_py lq_gi"><use xlink:href="#alpha"></use></svg></div></div><div><div class="iH_vW t_ei iH_Ek"><div class="iH_Ep"><h3 class="iH_Y s_9 t_eC iH_x6 aW_jn aW_jB aW_jR iH_Em s_dE"><a data-test-id="post-list-item-title" class="iH_L" href="/article/4644560-spy-3-buy-signals-i-am-waiting-for">SPY: 3 Buy Signals I Am Waiting For (NYSEARCA:SPY)</a></h3><footer class="kz_J aW_jl aW_jB aW_jQ" data-test-id="post-footer"></footer></div></div></div></article><article class="gL_gW fE_gW t_ei s_aw s_aU kM_Ig s_ak s_bo kM_Ig s_ak s_bo kM_Ik kM_Ik gL_z8" data-test-id="post-list-item"><div class="mr-18"><div class="flex shrink-0 items-center justify-center relative w-36 h-36 rounded-full" data-test-id="user-pic-wrapper"><img alt="Dividend Sensei profile picture" class="dark:text-black-100 flex w-full items-center justify-center overflow-hidden bg-white-96 text-white-96 dark:bg-black-30 rounded-full h-full" data-test-id="user-pic" height="36" loading="lazy" src="https://static3.seekingalpha.com/images/users_profile/047/572/571/big_pic.png" width="36"></div></div><div><div class="iH_vW t_ei iH_Ek"><div class="iH_Ep"><h3 class="iH_Y s_9 t_eC iH_x6 aW_jn aW_jB aW_jR iH_Em s_dE"><a data-test-id="post-list-item-title" class="iH_L" href="/article/4643431-10-high-yield-dividend-aristocrats-perfect-for-whats-coming-next">10 High-Yield Dividend Aristocrats Perfect For What's Coming Next</a></h3><footer class="kz_J aW_jl aW_jB aW_jQ" data-test-id="post-footer"><span class="oh_Ji" data-test-id="post-list-author">Dividend Sensei</span></footer></div></div></div></article><article class="gL_gW fE_gW t_ei s_aw s_aU kM_Ig s_ak s_bo kM_Ig s_ak s_bo kM_Ik kM_Ik gL_z8" data-test-id="post-list-item"><div class="mr-18"><div class="flex shrink-0 items-center justify-center relative w-36 h-36 rounded-full" data-test-id="user-pic-wrapper"><img alt="Tradevestor profile picture" class="dark:text-black-100 flex w-full items-center justify-center overflow-hidden bg-white-96 text-white-96 dark:bg-black-30 rounded-full h-full" data-test-id="user-pic" height="36" loading="lazy" src="https://static.seekingalpha.com/images/users_profile/001/003/408/big_pic.png" width="36"></div></div><div><div class="iH_vW t_ei iH_Ek"><div class="iH_Ep"><h3 class="iH_Y s_9 t_eC iH_x6 aW_jn aW_jB aW_jR iH_Em s_dE"><a data-test-id="post-list-item-title" class="iH_L" href="/article/4644414-altria-group-i-was-wrong-but-am-not-deterred">Altria Group: I Was Wrong But Am Not Deterred</a></h3><footer class="kz_J aW_jl aW_jB aW_jQ" data-test-id="post-footer"><span class="oh_Ji" data-test-id="post-list-author">Tradevestor</span></footer></div></div></div></article><article class="gL_gW fE_gW t_ei s_aw s_aU kM_Ig s_ak s_bo kM_Ig s_ak s_bo kM_Ik kM_Ik gL_z8" data-test-id="post-list-item"><div class="mr-18"><div class="flex shrink-0 items-center justify-center relative w-36 h-36 rounded-full" data-test-id="user-pic-wrapper"><img alt="Colorado Wealth Management Fund profile picture" class="dark:text-black-100 flex w-full items-center justify-center overflow-hidden bg-white-96 text-white-96 dark:bg-black-30 rounded-full h-full" data-test-id="user-pic" height="36" loading="lazy" src="https://static.seekingalpha.com/images/users_profile/014/527/192/big_pic.png" width="36"></div></div><div><div class="iH_vW t_ei iH_Ek"><div class="iH_Ep"><h3 class="iH_Y s_9 t_eC iH_x6 aW_jn aW_jB aW_jR iH_Em s_dE"><a data-test-id="post-list-item-title" class="iH_L" href="/article/4644122-disaster-strikes-mortgage-reits-under-siege">Disaster Strikes: Mortgage REITs Under Siege</a></h3><footer class="kz_J aW_jl aW_jB aW_jQ" data-test-id="post-footer"><span class="oh_Ji" data-test-id="post-list-author">Colorado Wealth Management Fund</span></footer></div></div></div></article><article class="gL_gW fE_gW t_ei s_aw s_aU kM_Ig s_ak s_bo kM_Ig s_ak s_bo kM_Ik kM_Ik gL_z8" data-test-id="post-list-item"><div class="mr-18"><div class="flex shrink-0 items-center justify-center relative w-36 h-36 rounded-full" data-test-id="user-pic-wrapper"><img alt="Steven Cress profile picture" class="dark:text-black-100 flex w-full items-center justify-center overflow-hidden bg-white-96 text-white-96 dark:bg-black-30 rounded-full h-full" data-test-id="user-pic" height="36" loading="lazy" src="https://static.seekingalpha.com/images/users_profile/050/113/560/big_pic.png" width="36"></div></div><div><div class="iH_vW t_ei iH_Ek"><div class="iH_Ep"><h3 class="iH_Y s_9 t_eC iH_x6 aW_jn aW_jB aW_jR iH_Em s_dE"><a data-test-id="post-list-item-title" class="iH_L" href="/article/4641618-seeking-alpha-vs-motley-fool">Seek Alpha: Don't Be A Fool</a></h3><footer class="kz_J aW_jl aW_jB aW_jQ" data-test-id="post-footer"><span class="oh_Ji" data-test-id="post-list-author">Steven Cress</span></footer></div></div></div></article></div></div></div></div></section><div class="rJ_Ry" id="comments-card"><section class="mx-auto flex w-full flex-col justify-between bg-white dark:bg-black-95 pt-24 md:pt-12 pb-24 px-safe-offset-18 md:pb-20 md:px-safe-or-24 mb-8 md:mb-18 print:block" data-test-id="comments-section"><div class="flex flex-col flex-wrap print:block"><div class="w-full max-w-full"><div class="rJ_p1"><div class="paywall-full-content"><div class="ov_MV t_ei t_ek s_dX" data-scroll-id="comments" data-test-id="comments-header" id="comments"><h4 class="ov_Y t_ei t_ek aW_jr aW_jH aW_jQ s_cU s_dA" data-test-id="comments-counter">Comments</h4><div><button aria-expanded="false" aria-label="Sort By" class="flex shrink-0 items-center justify-center text-large-r text-black-35 dark:text-black-10" data-test-id="sort-comments-button" type="button"><span class="truncate"><span class="rE_Rr t_ei t_ek"><span class="rE_Rs s_c3 aY_lE aW_jm aW_jC aW_jQ">Newest</span><div class="sX_SS rE_fv t_ei t_ek"><span class="rE_Rt"><svg viewBox="0 0 15 16" xmlns="http://www.w3.org/2000/svg"><path d="M0 0h6.15v3.7H0V0zm0 6.15h11.08v3.7H0v-3.7zm0 6.16h14.77V16H0v-3.7z"></path></svg></span></div></span></span></button></div><button aria-expanded="false" aria-label="Comment options" class="flex shrink-0 items-center justify-center text-large-r text-black-35 dark:text-black-10 rG_Rw s_co" data-test-id="dropdown" type="button"><span class="truncate"><span class="rG_os t_ei t_ek t_ep"><svg class="rG_Rv"><use xlink:href="#info"></use></svg></span></span></button></div><!--$--><div class="uK_g qo_g s_dU aP_i9" data-test-id="add-comment-form"><div class="uK_Pt qo_Pt t_ei"><div class="uK_E3 s_c9"><div class="flex shrink-0 items-center justify-center relative w-36 h-36 rounded-full" data-test-id="user-pic-wrapper"><div class="" data-test-id="user-pic"></div></div></div><div class="uK_Pu qo_Pu"><div aria-label="Comment content" class="border border-black-10 bg-white text-black placeholder:text-black-35 read-only:text-black-35 read-only:bg-black-5 dark:border-black-80 dark:bg-black-98 dark:text-black-10 placeholder:text-black-35 read-only:text-black-35 dark:placeholder:text-black-30 dark:read-only:text-black-30 focus:border-black-35 dark:focus:border-black-30 rounded-tl-0 rounded-bl-8 rounded-r-8 uK_Pv qo_Pv s_dS s_ah s_aC s_a0 s_bl uv_Vl" contenteditable="true" data-test-id="add-comment-input" placeholder="Be the first to comment" role="textbox" tabindex="0"></div><div class="uK_yi qo_yi t_ei t_ek t_eq"><button disabled="" class="J_0 t_ej t_ek t_ep J_fP J_fz aW_jm aW_jC aW_jR uK_Px qo_Px s_cy" data-test-id="publish-comment-button" type="button"><span class="">Publish</span></button></div></div></div></div><div></div><div class="wI_iM s_bR aW_jm aW_jB aW_jQ"><span>To report an error in this transcript<!-- -->, <button class="J_0 t_ej t_ek t_ep yl_YH" data-test-id="report-problem-with-article" type="button"><span class="">click here</span></button>.</span>Contact us to<!-- --> <a data-test-id="transcript-add-your-company" href="/page/contact?question=Transcript%20Inquiries">add your company</a> <!-- -->to our coverage or<!-- --> <a data-test-id="transcript-in-your-business" href="/page/contact?question=Transcript%20Inquiries">use transcripts in your business</a>. Learn more about Seeking Alpha transcripts<!-- --> <a data-test-id="learn-more-about-transcripts" href="/page/sa_transcripts">here</a>.<!-- --> <!-- -->Your feedback matters to us!</div><!--/$--></div></div></div></div></section></div><!--/$-->